Malignant pleural mesothelioma: recent developments : Current Opinion in Oncology Malignant
pleural mesothelioma: recent developments : Current Opinion in Oncology Log in or Register …

Antibodies have proven their high value in antitumor therapy over the last two decades.
They are currently being used as the first-choice to treat some of the most frequent …

Summary Background Tumour Treating Fields (TTFields) are a regional, antimitotic
treatment for solid tumours, which is based on the delivery of low-intensity alternating …

Mesothelioma is an aggressive cancer that is associated with exposure to asbestos.
Although asbestos is banned in several countries, including the UK, an epidemic of …

Malignant pleural mesothelioma (MPM) is an aggressive malignancy with a 5-year survival
rate of~ 10%. Since most patients present with irresectable disease, the vast majority is …

Mesothelin (MSLN) is considered a promising target for cancer therapy. Originally extracted
in 1992 after the immunization of mice with a human ovarian cancer (OC) cell line and …

Malignant pleural mesothelioma (MPM) represents the uncommon cancer originating from
pleural mesothelial cells, which is associated with dismal prognostic outcome. According to …

Malignant pleural mesothelioma (MPM) tumors are remarkably aggressive and most
patients only survive for 5–12 months; irrespective of stage; after primary symptoms appear …

Malignant pleural mesothelioma (MPM) is a highly aggressive form of cancer, with a median
survival of less than 1 year. It is well known that the hyaluronan (HA) receptor CD44 is highly …

OBJECTIVE. The purpose of this study was to develop a motion insensitive clinical dynamic
contrast-enhanced MRI (DCE-MRI) protocol to assess the response of pleural tumors in …